

LITERATURE CITATIONS

Chapter 2: Understanding Cancer

1. Sidransky D, Hollstein M. Clinical implications of the p53 gene. *Annu Rev Med.* 1996;47:285.
2. Chiba I, Takahashi T, Nau MM, et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. *Oncogene.* 1990;5(10):1603.
3. D'Amico D, Carbone D, Mitsudomi T, et al. High frequency of somatically acquired p53 mutations in small cell lung cancer cell lines and tumors. *Oncogene.* 1992;7(2):339.
4. Nesbitt JC, Putnam JB, Walsh GL, et al. Survival in early-stage non-small cell lung cancer. *Ann Thorac Surg.* 1995;60(2):466.
5. Ichinose Y, Hara N, Ohta M, et al. Is T factor of the TNM staging system a predominant prognostic factor in pathological stage I non-small cell lung cancer? a multivariate prognostic factor analysis of 151 patients. *J Thorac Cardiovasc Surg.* 1993;106(1):90.
6. Ichinose Y, Yano T, Asoh H, et al. Prognostic factors obtained by a pathological examination in completely resected non-small cell lung cancer. *J Thorac Cardiovasc Surg.* 1995;110(3):601.

Chapter 3: Lung Cancer Overview

1. World Health Organization. World Health Report 2002. World Health Reporting. Geneva, Switzerland. 2002.
2. Doll R, Hill AB. Smoking and carcinoma of the lung: preliminary report. *BMJ.* 1950;143:329.
3. Levin ML, Goldstein H, Gerhardt PR. Cancer and tobacco smoking: a preliminary report. *JAMA.* 1950;143:336.
4. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchogenic carcinoma. *JAMA.* 1950;143:329.
5. Schrek R, Baker LA, Ballard GP, et al. Tobacco smoking as an etiologic factor in disease. *Cancer Research.* 1950;10:49.
6. Mills CA, Porter MM. Tobacco smoking habits and cancer of the mouth and respiratory system. *Cancer Research.* 1950;10:539.
7. American Cancer Society. Cancer Facts & Figures 2001. American Cancer Society, Inc. Atlanta, Georgia. 2001.
8. US Department of Health and Human Services. Reducing the Health Consequences of Smoking: 25 Years of Progress. A Report of the Surgeon General. Centers for Disease Control and Prevention, Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health. Atlanta, Georgia. 1989.
9. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20,561 cases. *Ann Oncol.* 2002;13(7):1087.

10. Dales RE, Dionne G, Leech JA, Lunau M, Schweitzer I. Preoperative prediction of pulmonary complications following thoracic surgery. *Chest*. 1993;104(1):155.
11. Vaporciyan AA, Merriman KW, Ece F, et al. Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation. *Ann Thorac Surg*. 2002;73(2):420.
12. Kawahara M, Ushijima S, Kamimori T, et al. Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. *Br J Cancer*. 1998;78(3):409.
13. Wu S. [Clinical study on super-long-term survival over 15 years of postoperative patients with lung cancer]. *Zhonghua Zhong Liu Za Zhi*. 1993;15(3):227.
14. London WM. How addictive is cigarette smoking? *Priorities for Health*. 2000;12(3).
15. Nicotine Addiction in Britain: a report of the Tobacco Advisory Group of the Royal College of Physicians. Royal College of Physicians. London, England. 2000.
16. Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. *BMJ*. 2000;321(7257):355.
17. Carel R, Boffetta P, Kauppinen T, et al. Exposure to asbestos and lung and pleural cancer mortality among pulp and paper industry workers. *J Occup Environ Med*. 2002;44(6):579.
18. Pohlabein H, Wild P, Schill W, et al. Asbestos fiber-years and lung cancer: a two phase case-control study with expert exposure assessment. *Occup Environ Med*. 2002;59(6):410.
19. Wunsch-Filho V, Boffetta P, Colin D, Moncau JE. Familial cancer aggregation and the risk of lung cancer. *Sao Paulo Med J*. 2002;120(2):38.
20. Winer-Muram HT, Jennings SG, Tarver RD, et al. Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning. *Radiology*. 2002;223(3):798.
21. Shyu CL, Lee YC, Perng RP. Fast-growing squamous cell lung cancer. *Lung Cancer*. 2002;36(2):199.
22. Hasegawa M, Sone S, Takashima S, et al. Growth rate of small lung cancers detected on mass CT screening. *Br J Radiol*. 2000;73(876):1252.
23. Travis WD, Colby TV, Corrin B, et al. Histologic typing of lung and pleural tumors, 3rd Ed. Springer Verlag. Berlin, Germany. 1999.

Chapter 4: Lung Cancer Diagnosis and Staging

1. Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung cancer. A critique of the Mayo Lung Project. *Cancer*. 1991;67(4 Suppl):1155.
2. Chute CG, Greenberg ER, Baron J, et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. *Cancer*. 1985;56(8):2107.
3. Murray KL, Duvall E, Salter DM, Monaghan H. Efficacy and pattern of use of sputum cytology as a diagnostic test. *Cytopathology*. 2002;13(6):350.
4. Rangdaeng S, Ya-In C, Settakorn J, et al. Cytological diagnosis of lung cancer in Chiang Mai, Thailand: cyto-histological correlation and comparison of sensitivity of various methods. *J Med Assoc Thai*. 2002;85(9):953.

5. Tsubamoto M, Kuriyama K, Kido S, et al. Detection of lung cancer on chest radiographs: analysis on the basis of size and extent of ground-glass opacity at thin-section CT. *Radiology*. 2002;224(1):139.
6. Quekel LG, Goei R, Kessels AG, van Engelshoven JM. Detection of lung cancer on the chest radiograph: impact of previous films, clinical information, double reading, and dual reading. *J Clin Epidemiol*. 2001;54(11):1146.
7. Quekel LG, Kessels AG, Goei R, van Engelshoven JM. Detection of lung cancer on the chest radiograph: a study on observer performance. *Eur J Radiol*. 2001;39(2):111.
8. Tsukuda S, Heshiki A, Katsuragawa S, Li Q, MacMahon H, Doi K. Detection of lung nodules on digital chest radiographs: potential usefulness of a new contralateral subtraction technique. *Radiology*. 2002;223(1):199.
9. Li Q, Katsuragawa S, Doi K. Computer-aided diagnostic scheme for lung nodule detection in digital chest radiographs by use of a multiple-template matching technique. *Med Phys*. 2001;28(10):2070.
10. Vesselle H, Pugsley JM, Vallieres E, Wood DE. The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer. *J Thorac Cardiovasc Surg*. 2002;124(3):511.
11. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. *J Clin Oncol*. 1999;17(10):3201.
12. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. *Eur J Nucl Med*. 1998;25(9):1244.
13. Schmid RA, Hillinger S, Bruchhaus H, et al. [Detection of unexpected extrathoracic metastases in preoperative staging of non-small-cell bronchial carcinoma (NSCLC) with positron emission tomography (PET)]. *Langenbecks Arch Chir Suppl Kongressbd*. 1998;115:1264.
14. Graeter TP, Hellwig D, Hoffmann K, Ukena D, Kirsch CM, Schafers HJ. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. *Ann Thorac Surg*. 2003;75(1):231.
15. Kiernan PD, Sheridan MJ, Lamberti J, et al. Mediastinal staging of non-small cell lung carcinoma using computed and positron-emission tomography. *South Med J*. 2002;95(10):1168.
16. Scott WJ. Positron emission tomography (PET) and combined imaging modalities for staging lung cancer. *Surg Clin North Am*. 2002;82(3):477.
17. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. *Radiology*. 2002;225(2):575.
18. Steinert HC, von Schulthess GK. Initial clinical experience using a new integrated in-line PET/CT system. *Br J Radiol*. 2002;75(SpecNo):S36.

Chapter 5: Lung Cancer Treatment Overview

1. Komaki R, Lee JS, Kaplan B, et al. Randomized phase III study of amifostine in patients treated with chemoradiation for inoperable stage II-III non-small cell lung cancer (NSCLC). *Int J Radiat Oncol Biol Phys.* 2001;51(Suppl 1):19.
2. Tannehill SP, Mehta MP, Larson M, Storer B, Pellet J, Kinsella TJ, Schiller JH. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. *J Clin Oncol.* 1997;15(8):2850.
3. Silvestri GA, Handy J, Lackland D, et al. Specialists achieve better outcomes than generalists for lung cancer surgery. *Chest.* 1998;114:675.
4. Laroche C, Wells F, Coulden R, et al. Improving surgical resection rate in lung cancer. *Thorax.* 1998;53:445.
5. Schroen AT, Detterbeck FC, Crawford R, et al. Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer. *Chest.* 2000;118:129.
6. Bach PB, Cramer LD, Schrag D, et al. The influence of hospital volume on survival after resection for lung cancer. *N Engl J Med.* 2001;345:181.
7. Smythe WR. Treatment of stage I non-small cell lung carcinoma. *Chest.* 2003;123:181S.
8. Keller SM, Adak S, Wagner H, et al. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. *Ann Thorac Surg.* 2000;70:358.
9. Nomori H, Horio H, Naruke T, et al. What is the advantage of a thoracoscopic lobectomy over a limited thoracotomy procedure for lung cancer surgery? *Ann Thorac Surg.* 2001;72:879.
10. Rovario G, Varoli F, Vergani C, et al. Video-assisted thoracoscopic surgery (VATS) major pulmonary resections: the Italian experience. *Semin Thorac Cardiovasc Surg.* 1998;10:313.
11. McKenna RJ Jr. Lobectomy by video-assisted thoracic surgery with mediastinal lymph node sampling for lung cancer. *Thorac Cardiovasc Surg.* 1994;107:879.
12. Lewis RJ. The role of video-assisted thoracic surgery for carcinoma of the lung: wedge resection to lobectomy by simultaneous individual stapling. *Ann Thorac Surg.* 1993;56:784.

Chapter 6: Treatment of Small Cell Lung Cancer

1. National Comprehensive Cancer Network[®] Practice Guidelines in Oncology: Small Cell Lung Cancer, Version 1.2002. National Comprehensive Cancer Network[®], Inc. Rockledge, Pennsylvania. 2001.
2. Hauber HP, Bohuslavizki KH, Lund CH, et al. Positron emission tomography in the staging of small-cell lung cancer: a preliminary study. *Chest.* 2001;119:950.
3. Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. *Eur J Nucl Med.* 2001;28:483.
4. Simon GR, Wagner H. Small cell lung cancer. *Chest.* 2003;123:259S.
5. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. *J Clin Oncol.* 1993;11(2):336.

6. Johnson BE, Bridges JD, Sobczek M, et al. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. *J Clin Oncol.* 1996;14(3):806.
7. Turrisi AT III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med.* 1999;340(4):265.
8. Fry WA, Menck HR, Winchester DP. The National Cancer Data Base report on lung cancer. *Cancer.* 1996;77(9):1947.
9. Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung cancer: post-treatment characteristics in patients surviving 5 to 18+ years – an analysis of 1,714 consecutive patients. *J Clin Oncol.* 1995;13(5):1215.
10. Johnson BE, Grayson J, Makuch RW, et al. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. *J Clin Oncol.* 1990;8(3):396.
11. Videtic GM, Stitt L. Patients who smoke during concurrent chemoradiation (ChT/RT) for limited small cell lung cancer (LSCLC) have decreased survival. Program and abstracts of the American Society of Clinical Oncology 38th Annual Meeting, May 18-21, 2002; Orlando, Florida. Abstract 1176.
12. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol.* 1982;5:649.
13. Simon G, Ginsberg RJ, Ruckdeschel JC. Small-cell lung cancer. *Chest Surg Clin N Am.* 2001;11:165.
14. Bleehen NM, Fayers PM, Girling DJ, et al. Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small cell lung cancer. *Resp Med.* 1989;83:51.
15. Lowenbraun S, Bartolucci A, Smalley RV, et al. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. *Cancer.* 1979;44:406.
16. Alberto P, Brunner KW, Martz G, et al. Treatment of bronchiogenic carcinoma with simultaneous or sequential combination chemotherapy, including methotrexate, cyclophosphamide, procarbazine and vincristine. *Cancer.* 1976;38:2208.
17. Ihde DC. Chemotherapy of lung cancer. *N Engl J Med.* 1992;327:1434.
18. Bishop JF, Raghavan D, Stuart-Harris R, et al. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small cell lung cancer. *J Clin Oncol.* 1987;5:1574.
19. Pujol JL, Daures JP, Riviere A, et al. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. *J Natl Cancer Inst.* 2001;93:300.
20. Loehrer PJ, Ansari R, Gonin R, et al. Cisplatin plus etoposide with or without ifosfamide in extensive small cell lung cancer: a Hoosier oncology group study. *J Clin Oncol.* 1995;13:2594.
21. Miyamoto H, Nakabayashi T, Isobe H, et al. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small cell lung cancer. *Oncology.* 1992;49:431.

22. Cull A, Gregor A, Hopwood P, et al. Neurological and cognitive impairment in long-term survivors of small cell lung cancer. *Eur J Cancer*. 1994;30A(8):1067.

Chapter 7: Treatment for Non-Small Cell Lung Cancer

1. Travis WD, Colby TV, Corrin B, et al. Histologic typing of lung and pleural tumors, 3rd Ed. Springer Verlag. Berlin, Germany. 1999.
2. Bülzebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification. *Cancer*. 1992;70:1102.
3. Fry WA, Menck HR, Winchester DP. The National Cancer Data Base Report on lung cancer. *Cancer*. 1996;77:1947.
4. Naruke T, Goya T, Tsuchiya R, et al. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis. *Ann Thorac Surg*. 1988;46:603.
5. National Comprehensive Cancer Network[®] Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, Version 1.2002. National Comprehensive Cancer Network[®], Inc. Rockledge, Pennsylvania. 2001
6. Kerstine KH, Trapp JF, Croft DR, et al. Comparison of positron emission tomography (PET) and computed tomography (CT) to identify N2 and N3 disease in non-small cell lung cancer (NSCLC). *Proc Am Soc Clin Oncol*. 1998;17:458.
7. Chin R, Ward R, Keys JW. Mediastinal staging of non-small cell lung cancer with positron emission tomography. *Am J Respir Crit Care Med*. 1995;152:2090.
8. Kerr KM, Lamb D, Wathen CG, et al. Pathological assessment of mediastinal lymph nodes in lung cancer: Implications for non-invasive mediastinal staging. *Thorax*. 1992;47:337.
9. Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F. The non-invasive staging of non-small cell lung cancer. *Chest*. 2003;123:147S.
10. Harpole DH, Herndon JE, Young WG, et al. Stage I non-small cell lung cancer: a multivariate analysis of treatment methods and patterns of recurrence. *Cancer*. 1995;76:787.
11. Firat S, Byhardt RW, Gore E. Comorbidity and Karnofsky performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys*. 2002;54(2):357.
12. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol*. 1982;5:649.
13. Myrdal G, Lambe M, Gustafsson G, Nilsson K, Stahle E. Survival in primary lung cancer potentially cured by operation: influence of tumor stage and clinical characteristics. *Ann Thorac Surg*. 2003;75(2):356.
14. Mountain CF. Revisions in the international system for staging lung cancer. *Chest*. 1997;111:1710.
15. Furuse K, Fukuoka M, Kato H, et al. A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group. *J Clin Oncol*. 1993;11(10):1852.

16. Edell ES, Cortese DA. Photodynamic therapy in the management of early superficial squamous cell carcinoma as an alternative to surgical resection. *Chest.* 1992;102(5):1319.
17. Van Boxem T, Venmans B, Schramel F, et al. Radiographically occult lung cancer treated with fiberoptic bronchoscopic electrocautery: a pilot study of a simple and inexpensive technique. *Eur Respir J.* 1998;11:169.
18. Deygas N, Froudarakis M, Ozenne G, et al. Cryotherapy in early superficial bronchogenic carcinoma. *Chest.* 2001;120:26.
19. Marsiglia H, Baldeyrou P, Lartigau E, et al. High-dose-rate brachytherapy as sole modality for early-stage endobronchial carcinoma. *Int J Radiat Oncol Biol Phys.* 2000;47:665.
20. Perol M, Caliendo R, Pommier P, et al. Curative irradiation for limited endobronchial carcinomas with high dose brachytherapy: results of a pilot study. *Chest.* 1997;111:1417.
21. Smythe WR. Treatment of stage I non-small cell lung carcinoma. *Chest.* 2003;123:181S.
22. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence in second primary tumors in resected stage I lung cancer. *Thorac Cardiovasc Surg.* 1995;89:836.
23. Ginsberg RJ, Rubinstein LV. A randomized comparative trial of lobectomy vs limited resection for patients with T1N0 non-small cell lung cancer. *Lung Cancer.* 1995;7:83.
24. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. *Thorax.* 2001;56:628.
25. Robinson LA, Wagner H Jr, Ruckdeschel JC, et al. Treatment of stage IIIA non-small cell lung cancer. *Chest.* 2003;123:202S.
26. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group Experience. *J Clin Oncol.* 1991;9:1618.
27. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group Study. *J Clin Oncol.* 1986;4:702.
28. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. *J Clin Oncol.* 1986;4:1604.
29. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. *J Natl Cancer Inst.* 1980;65:25.
30. Lanzotti VJ, Thomas DR, Boyle LE, et al. Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria. *Cancer.* 1977;39:303.
31. Socinski MA, Morris DE, Masters GA, Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer. *Chest.* 2003;123:226S.
32. Detterbeck FC, Bleiweis MS, Ewend MG. Surgical treatment of stage IV non-small cell lung cancer. In: Detterbeck FC, Rivera MP, Socinski MA, et al, eds. Diagnosis and treatment of lung cancer: An evidence-based guide for the practicing clinician. WB Saunders. Philadelphia, PA. 2001.
33. Porte H, Siat J, Guibert B, et al. Resection of adrenal metastases from non-small cell lung cancer: A multi-institutional study. *Ann Thorac Surg.* 2001;71:981.

34. Pham DT, Dean DA, Detterbeck FC. Adrenalectomy as the new treatment paradigm for solitary adrenal metastasis from lung cancer. Paper presented at: The Society of Thoracic Surgeons Thirty-seventh Annual Meeting. January 30, 2001. New Orleans, Louisiana.
35. Socinski M. Chemotherapy for stage IV non-small cell lung cancer. In: Detterbeck FC, Rivera MP, Socinski MA, et al, eds. Diagnosis and treatment of lung cancer: An evidence-based guide for the practicing clinician. WB Saunders. Philadelphia, PA. 2001.
36. Colice GL, Rubins J, Unger M. Follow-up and surveillance of the lung cancer patient following curative-intent therapy. *Chest*. 2003;123:272S.

Chapter 9: Living With Lung Cancer

1. Kübler Ross E. On Death and Dying. Simon & Schuster. New York, New York. 1969.
2. Miller SM. Monitoring versus blunting styles of coping with cancer influence the information patients want and need about their disease. Implications for cancer screening and management. *Cancer*. 1995;76(2):167.
3. Steptoe A, O'Sullivan J. Monitoring and blunting coping styles in women prior to surgery. *Br J Clin Psychol*. 1986;25(Pt 2):143.
4. Miller SM, Mangan CE. Interacting effects of information and coping style in adapting to gynecologic stress: should the doctor tell all? *J Pers Soc Psychol*. 1983;45(1):223.
5. Ebright PR, Lyon B. Understanding hope and factors that enhance hope in women with breast cancer. *Qual Lif Res*. 2002;11(2):101.
6. Kyngas H, Mikkonen R, Nousiainen EM, et al. Coping with the onset of cancer: coping strategies and resources of young people with cancer. *Eur J Cancer Care (Engl)*. 2001;10(1):6.
7. Petticrew M, Bell R, Hunter D. Influence of psychological coping on survival and recurrence in people with cancer: systematic review. *BMJ*. 2002;325(7372):1066.
8. London WM. How addictive is cigarette smoking? *Priorities for Health*. 2000;12(3).
9. Nicotine Addiction in Britain: a report of the Tobacco Advisory Group of the Royal College of Physicians. Royal College of Physicians. London, England. 2000.
10. National Institute on Drug Abuse. NIDA Research Report - Nicotine Addiction. NIH Publication No. 01-4342. National Institutes of Health. Bethesda, Maryland. 2002.
11. National Institute of Mental Health. Depression. NIH Publication No. 02-3561. National Institutes of Health. Bethesda, Maryland. 2002.

Chapter 10: Supportive Care

1. Grippi MA. Clinical aspects of lung cancer. *Semin Roentgenol*. 1990;25:12.
2. Andersen HA, Prakash UBS. Diagnosis of symptomatic lung cancer. *Semin Respir Med*. 1982;3:165.
3. Johnston WW. The malignant pleural effusion: a review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. *Cancer*. 1985;56:905.
4. Cohen S, Hossain SA. Primary carcinoma of the lung: a review of 417 histologically proved cases. *Dis Chest*. 1966;49:67.

5. Emerson GL, Emerson MS, Sherwood CE. The natural history of carcinoma of the lung. *J Thorac Surg.* 1959;37:291.
6. Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. *Am J Med.* 1977;63:695.
7. Simons JP, Schols AM, Buurman WA, Wouters EF. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. *Clin Sci (Lond).* 1999;97(2):215.
8. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. *J Clin Oncol.* 2002;20(2):567.
9. Langer CJ, Hoffman JP, Ottery FD. Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia. *Nutrition.* 2001;17(1 Suppl):S1.
10. Lyden E, Cvetkovska E, Westin T, et al. Effects of nandrolone propionate on experimental tumor growth and cancer cachexia. *Metabolism.* 1995;44(4):445.
11. Beckles MA, Spiro SG, Colice GL, Rudd RM. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. *Chest.* 2003;123:97S.
12. National Institute of Mental Health. Depression. NIH Publication No. 02-3561. National Institutes of Health. Bethesda, Maryland. 2002.
13. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. *Oncologist.* 2002;7(6):492.
14. Meyers, C. & Abbruzzese, J. Cognitive functioning in cancer patients: Effect of previous treatment. *Neurology.* 1992;42:434.
15. Jackson DV, Wells HB, Atkins JN, et al. Amelioration of vincristine neurotoxicity by glutamic acid. *Am J Med.* 1988;84:1016.
16. Di Re F, Bohm S, Oriana S, Spatti GB, Zunino F. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer. *Cancer Chemother Pharmacol.* 1990;25(5):355.
17. Lersch C, Schmelz R, Eckel F, et al. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. *Clin Colorectal Cancer.* 2002;2(1):54.
18. Koukourakis MI, Giatromanolaki A, Kakolyris S, Froudarakis M, Georgoulas V, Retalis G, Bahlitzanakis N. Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer. *Med Oncol.* 2000;17(2):135.
19. MaCaffery M, Pasero C. Pain: Clinical Manual (2nd Ed). Mosby. St. Louis, Missouri. 1999.
20. Cancer Pain Relief and Palliative Care. World Health Organization. Geneva, Switzerland. 1990.
21. Schug SA, Zech D, Grond S, Jung H, Meuser T, Stobbe B. A long-term survey of morphine in cancer pain patients. *J Pain Symptom Manage.* 1992;7:259.
22. Friedman DP. Perspectives on the medical use of drugs of abuse. *J Pain Symptom Manage.* 1990;5(1 Suppl):S2.

23. Chapman CR, Hill HF. Prolonged morphine self-administration and addiction liability: evaluation of two theories in a bone marrow transplant unit. *Cancer*. 1989;63:1636.
24. Kanner RM, Foley KM. Patterns of narcotic drug use in a cancer pain clinic. *Ann N Y Acad Sci*. 1981;362:161.
25. Porter J, Jick H. Addiction rare in patients treated with narcotics. *N Engl J Med*. 1980;302:123.

Chapter 11: Complementary Healing

1. Shi Y, Devadas S, Greeneltch KM, Yin D, Allan Mufson R, Zhou J. Stressed to death: implication of lymphocyte apoptosis for psychoneuroimmunology. *Brain Behav Immun*. 2003;17(1 Suppl):18.
2. Dhabhar FS. Stress-induced augmentation of immune function – the role of stress hormones, leukocyte trafficking, and cytokines. *Brain Behav Immun*. 2002;16(6):785.
3. Farag NH, Nelesen RA, Dimsdale JE, Loreda JS, Mills PJ. The effects of acute psychological stress on lymphocyte adhesion molecule expression and density in cardiac versus vascular reactors. *Brain Behav Immun*. 2002;16(4):411.
4. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Psychoneuroimmunology: psychological influences on immune function and health. *J Consult Clin Psychol*. 2002;70(3):537.
5. Pruett SB. Quantitative aspects of stress-induced immunomodulation. *Int Immunopharmacol*. 2001;1(3):507.
6. Kreitler S, Aronson M, Berliner S, Kreitler H, Weissler K, Arber N. Life events and personal problems: their psychological and emotional effects. *Pers Individ Dif*. 1995;18:101.
7. Benschop RJ, Nieuwenhuis EES, Tromp EAM, Godaert GLR, Ballieux RE, vanDoornen, LJP. Effects of beta-adrenergic blockade on immunologic and cardiovascular changes induced by mental stress. *Circulation*. 1994;89:762.
8. Brosschot JF, Benschop RJ, Bodaert GLR, et al. Influence of life stress on immunological reactivity to mild psychological stress. *Psychosom Med*. 1994;56:216.
9. Futterman AD, Kemeny ME, Shapiro D, Fahey JJ. Immunological and physiological changes associated with induced positive and negative mood. *Psychosom Med*. 1994;56:499.
10. Brosschot JF, Benschop RJ, Godaert GLR, DeSmet MBM, Olf M, Heijnen CJ, Ballieux RE. Effects of experimental psychological stress on distribution and function of peripheral blood cells. *Psychosom Med*. 1992;54:394.
11. Kiecolt-Glaser JK, Cacioppo JT, Malarkey WB, Glaser R. Acute psychological stressors and short-term immune changes: what, why, for whom, and to what extent? *Psychosom Med*. 1992;54:680.
12. Zakowski S, Hall MH, Baum A. Stress, stress management, and the immune system. *Appl Prev Psychol*. 1992;1:1.
13. Manuck SB, Cohen S, Rabin BS, Muldoon MF, Bachen EA. Individual differences in cellular immune response to stress. *Psychol Sci*. 1991;2:111.
14. Naliboff BD, Benton D, Solomon GF, et al. Immunological changes in young and old adults during brief laboratory stress. *Psychosom Med*. 1991;53:121.

15. Moore NC. A review of EEG biofeedback treatment of anxiety disorders. *Clin Electroencephalogr.* 2000;31(1):1.
16. Leahy A, Clayman C, Mason I, Lloyd G, Epstein O. Computerized biofeedback games: a new method for teaching stress management and its use in irritable bowel syndrome. *J R Coll Physicians Lond.* 1998;32(6):552.
17. Jacavone J, Young J. Use of pulmonary rehabilitation strategies to wean a difficult-to-wean patient: case study. *Crit Care Nurse.* 1998;18(6):29.
18. Landis B, Romano PM. A scoring system for capnogram biofeedback: preliminary findings. *Appl Psychophysiol Biofeedback.* 1998;23(2):75.
19. Breitbart W. Psychiatric management of cancer pain. *Cancer.* 1989;63(11 Suppl):2336.
20. Aronoff GM. The use of non-narcotic drugs and other alternatives for analgesia as part of a comprehensive pain management program. *J Med.* 1982;13(3):191.
21. Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. *J Pain Symptom Manage.* 2000;20(5):374.
22. Vickers AJ, Cassileth BR. Unconventional therapies for cancer and cancer-related symptoms. *Lancet Oncol.* 2001;2(4):226.
23. Marchand P, Moulin JL, Merle JC. [Hypnosis for treatment of nausea and vomiting: it works!]. *Rev Med Liege.* 2002;57(6):382.
24. Marchioro G, Azzarello G, Viviani F, et al. Hypnosis in the treatment of anticipatory nausea and vomiting in patients receiving cancer chemotherapy. *Oncology.* 2000;59(2):100.
25. Gall TL, Cornblat MW. Breast cancer survivors give voice: a qualitative analysis of spiritual factors in long-term adjustment. *Psychooncology.* 2002;11(6):524.
26. Chibnall JT, Videen SD, Duckro PN, Miller DK. Psychosocial-spiritual correlates of death distress in patients with life-threatening medical conditions. *Palliat Med.* 2002;16(4):331.
27. Abernethy AD, Chang HT, Seidlitz L, Evinger JS, Duberstein PR. Religious coping and depression among spouses of people with lung cancer. *Psychosomatics.* 2002;43(6):456.
28. Nelson CJ, Rosenfeld B, Breitbart W, Galietta M. Spirituality, religion, and depression in the terminally ill. *Psychosomatics.* 2002;43(3):213.
29. Efficace F, Marrone R. Spiritual issues and quality of life assessment in cancer care. *Death Stud.* 2002;26(9):743.
30. Peretz A, Néve J, Desmedt J, et al. Lymphocyte response is enhanced by supplementation of elderly subjects with selenium-enriched yeast. *Am J Clin Nutr.* 1991;53:1323.
31. Redman C, Xu MJ, Peng YM, et al. Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. *Carcinogenesis.* 1997;18:1195.
32. Lu J, Pei H, Ip C, et al. Effect on an aqueous extract of selenium-enriched garlic on in vitro markers and in vivo efficacy in cancer prevention. *Carcinogenesis.* 1996;17:1903.

33. Wilson AC, Thompson HJ, Schedin PJ, et al. Effect of methylated forms of selenium on cell viability and the induction of DNA strand breakage. *Biochem Pharmacol.* 1992;43:1137.
34. Burney PGJ, Comstock GW, Morris JS. Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. *Am J Clin Nutr.* 1989;49:895.
35. Toma S, Micheletti A, Giacchero A, et al. Selenium therapy in patients with precancerous and malignant oral cavity lesions: preliminary results. *Cancer Detection Prev.* 1991;15:491.
36. Willett WC, Polk BF, Morris JS, et al. Prediagnostic serum selenium and risk of cancer. *Lancet.* 1983;42:130.
37. Helzlsouer KJ, Comstock GW, Morris JS. Selenium, lycopene, alpha-tocopherol, β -carotene, retinol, and subsequent bladder cancer. *Cancer Res.* 1989;49:6144.
38. Jaskiewicz K, Marasas WF, Rossouw JE, et al. Selenium and other mineral elements in populations at risk for esophageal cancer. *Cancer.* 1988;62:2635.
39. Knekt P, Aromaa A, Maatela J, et al. Serum selenium and subsequent risk of cancer among Finnish men and women. *J Natl Cancer Inst.* 1990;82:864.
40. Yu M-W, Horng I-S, Hsu K-H, et al. Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. *Am J Epidemiol.* 1999;150:367.
41. Scieszka M, Danch A, Machalski M, Drozd M. Plasma selenium concentration in patients with stomach and colon cancer in the Upper Silesia. *Neoplasma.* 1997;44:395.
42. Knekt P, Marniemi J, Teppo L, et al. Is low selenium status a risk factor for lung cancer? *Am J Epidemiol.* 1998;148:975.
43. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. *JAMA.* 1996;276:1957.
44. Allen JI, Bell E, Boosalis MG, et al. Association between urinary zinc excretion and lymphocyte dysfunction in patients with lung cancer. *Am J Med.* 1985;79:209.
45. Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H. Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. *Biochem Biophys Res Commun.* 1997;234(2):296.
46. Hayashi A, Gillen AC, Lott JR. Effects of daily oral administration of quercetin chalcone and modified citrus pectin. *Altern Med Rev.* 2000;5(6):546.
47. Huang EY, Leung SW, Wang CJ, et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. *Int J Radiat Oncol Biol Phys.* 2000;46(3):535.
48. Okuno SH, Woodhouse CO, Loprinzi CL, et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. *Am J Clin Oncol.* 1999;22(3):258.
49. Vahdat L, Papadopoulos K, Lange D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. *Clin Cancer Res.* 2001;7(5):1192.
50. Fox CH, Eberl M. Phytic acid (IP6), novel broad spectrum anti-neoplastic agent: a systematic review. *Complement Ther Med.* 2003;10(4):229.

51. Singh RP, Agarwal C, Agarwal R. Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. *Carcinogenesis*. 2003;24(3):555.
52. El-Sherbiny YM, Cox MC, Ismail ZA, Shamsuddin AM, Vucenik I. G0/G1 arrest and S phase inhibition of human cancer cell lines by inositol hexaphosphate (IP6). *Anticancer Res*. 2001;21(4A):2393.
53. Zi X, Singh RP, Agarwal R. Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. *Carcinogenesis*. 2000;21(12):2225.
54. Maestroni GJM. The immunoneuroendocrine role of melatonin. *J Pineal Res*. 1993;14:1.
55. Maestroni GJM, Conti A. Anti-stress role of melatonin-immuno-opioid network: Evidence for a physiological mechanism involving T cell-derived immunoreactive b-endorphin and MET-enkephalin binding to thymic opioid receptors. *Int J Neurosci*. 1991;61:289.
56. Maestroni GJM, Conti A. The pineal neurohormone melatonin stimulates activated CD4+, Thy-1+ cells to release opioid agonist(s) with immunoenhancing and anti-stress properties. *J Neuroimmunol*. 1990;28:167.
57. Maestroni GJM, Conti A. Beta-endorphin and dynorphin mimic the circadian immunoenhancing and anti-stress effects of melatonin. *Int J Immunopharmacol*. 1989;11:333.
58. Lissoni P, Rovelli F, Malugani F, et al. Anti-angiogenic activity of melatonin in advanced cancer patients. *Neuroendocrinol Lett*. 2001;22:45.
59. Lissoni P, Paolorossi F, Ardizzoia A, et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. *J Pineal Res*. 1997;23:15.
60. Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? *Eur J Cancer*. 1996;32:1340.
61. Lissoni P, Barni S, Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: A phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. *Br J Cancer*. 1995;71:854.
62. Lissoni P, Barni S, Ardizzoia A, et al. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. *Cancer*. 1994;73:699.
63. Lissoni P, Barni S, Cattaneo G, et al. Clinical results with pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. *Oncology*. 1991;48:448.
64. Lissoni P, Barni S, Tancini G, et al. Clinical study of melatonin in untreatable advanced cancer patients. *Tumori*. 1987;73:475.
65. Hirazumi A, Furusawa E. An immunomodulatory polysaccharide-rich substance from the fruit juice of *Morinda citrifolia* (noni) with antitumour activity. *Phytother Res*. 1999;13(5):380.
66. Liu G, Bode A, Ma WY, Sang S, Ho CT, Dong Z. Two novel glycosides from the fruits of *Morinda citrifolia* (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line. *Cancer Res*. 2001;61(15):5749.

67. Pezzella F, Pastorino U, Tagliabue E, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. *Am J Pathol.* 1997;151(5):1417.
68. Weber MH, Lee J, Orr FW. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. *Int J Oncol.* 2002;20(2):299.
69. Gingras D, Batist G, Beliveau R. AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. *Expert Rev Anticancer Ther.* 2001;1(3):341.
70. Sheu JR, Fu CC, Tsai ML, Chung WJ. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. *Anticancer Res.* 1998;18(6A):4435.
71. McGuire TR, Kazakoff PW, Hoie EB, Fienhold MA. Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium. *Pharmacotherapy.* 1996;16(2):237.
72. Barber R, Delahunt B, Grebe SK, Davis PF, Thornton A, Slim GC. Oral shark cartilage does not abolish carcinogenesis but delays tumor progression in a murine model. *Anticancer Res.* 2001;21(2A):1065.
73. Horsman MR, Alsner J, Overgaard J. The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma. *Acta Oncol.* 1998;37(5):441.
74. Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. *J Clin Oncol.* 1998;16(11):3649.
75. Myoung H, Hong SP, Yun PY, Lee JH, Kim MJ. Anti-cancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion. *Cancer Sci.* 2003;94(2):215.
76. Buchler P, Gukovskaya AS, Mouria M, et al. Prevention of metastatic pancreatic cancer growth in vivo by induction of apoptosis with genistein, a naturally occurring isoflavonoid. *Pancreas.* 2003;26(3):264.
77. Seike N, Wanibuchi H, Morimura K, et al. Enhancement of lung carcinogenesis by nonylphenol and genistein in a F344 rat multiorgan carcinogenesis model. *Cancer Lett.* 2003;192(1):25.
78. Thigpen JE, Locklear J, Haseman JK, Saunders H, Grant MF, Forsythe DB. Effects of the dietary phytoestrogens daidzein and genistein on the incidence of vulvar carcinomas in 129/J mice. *Cancer Detect Prev.* 2001;25(6):527.
79. Kurashige S, Akuzawa Y, Endo F. Effects of astragali radix extract on carcinogenesis, cytokine production, and cytotoxicity in mice treated with a carcinogen, N-butyl-N'-butanolnitrosoamine. *Cancer Invest.* 1999;17(1):30.
80. Sinclair S. Chinese herbs: a clinical review of Astragalus, Ligusticum, and Schizandrae. *Altern Med Rev.* 1998;3(5):338.
81. Chu DT, Lepe-Zuniga J, Wong WL, LaPushin R, Mavligit GM. Fractionated extract of *Astragalus membranaceus*, a Chinese medicinal herb, potentiates LAK cell cytotoxicity generated by a low dose of recombinant interleukin-2. *J Clin Lab Immunol.* 1988;26:183.
82. Sadava D, Ahn J, Zhan M, Pang ML, Ding J, Kane SE. Effects of four Chinese herbal extracts on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. *Cancer Chemother Pharmacol.* 2002;49(4):261.

83. Cheng XD, Guo F, Liu JX. [Study on therapeutic effect and immunological mechanism of fuzhengfang herbs in mice with Lewis lung cancer]. *Zhongguo Zhong Xi Yi Jie He Za Zhi*. 1997;17(2):88.
84. Huang ZM, Long H. [Therapeutic effect of Chinese medicinal herbs combined with chemotherapy on advanced non-small cell lung cancer]. *Zhongguo Zhong Xi Yi Jie He Za Zhi*. 1997;17(1):26.
85. Hirose M, Yamaguchi T, Lin C, et al. Effects of arctiin on PhIP-induced mammary, colon and pancreatic carcinogenesis in female Sprague-Dawley rats and MeIQx-induced hepatocarcinogenesis in male F344 rats. *Cancer Lett*. 2000;155(1):79.
86. Shi YQ, Fukai T, Sakagami H, et al. Cytotoxic and DNA damage-inducing activities of low molecular weight phenols from rhubarb. *Anticancer Res*. 2001;21(4A):2847.
87. Morre DJ, Morre DM, Sun H, Cooper R, Chang J, Janle EM. Tea catechin synergies in inhibition of cancer cell proliferation and of a cancer specific cell surface oxidase (ECTO-NOX). *Pharmacol Toxicol*. 2003;92(5):234.
88. Maeda-Yamamoto M, Suzuki N, Sawai Y, Miyase T, Sano M, Hashimoto-Ohta A, Isemura M. Association of suppression of extracellular signal-regulated kinase phosphorylation by epigallocatechin gallate with the reduction of matrix metalloproteinase activities in human fibrosarcoma HT1080 cells. *J Agric Food Chem*. 2003;51(7):1858.
89. Sachinidis A, Hescheler J. Are catechins natural tyrosine kinase inhibitors? *Drug News Perspect*. 2002;15(7):432.
90. Jatoi A, Ellison N, Burch PA, et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. *Cancer*. 2003;97(6):1442.
91. Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. *Oncology*. 2002;62 Suppl 1:94.
92. Kao ST, Yeh CC, Hsieh CC, Yang MD, Lee MR, Liu HS, Lin JG. The Chinese medicine Bu-Zhong-Yi-Qi-Tang inhibited proliferation of hepatoma cell lines by inducing apoptosis via G0/G1 arrest. *Life Sci*. 2001;69(13):1485.
93. Kvasnicka F, Biba B, Sevcik R, Voldrich M, Kratka J. Analysis of the active components of silymarin. *J Chromatogr A*. 2003;990(1-2):239.
94. Katiyar SK. Treatment of silymarin, a plant flavinoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin. *Int J Oncol*. 2002;21(6):1213.
95. Singh RP, Agarwal R. Flavinoid antioxidant silymarin and skin cancer. *Antioxid Redox Signal*. 2002;4(4):655.
96. Kosina P, Kren V, Gebhardt R, Grambal F, Ulrichova J, Walterova D. Antioxidant properties of silybin glycosides. *Phytother Res*. 2002;16 Suppl 1:S33.
97. Sharma Y, Agarwal C, Singh AK, Agarwal R. Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells. *Mol Carcinog*. 2001;30(4):224.
98. Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. *Cancer Res*. 2000;60(20):5617.

99. Zhao J, Lahiri-Chatterjee M, Sharma Y, Agarwal R. Inhibitory effect of a flavinoid antioxidant silymarin on benzoyl peroxide-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin. *Carcinogenesis*. 2000;21(4):811.
100. Zi X, Feyes DK, Agarwal R. Anticarcinogenic effect of a flavinoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. *Clin Cancer Res*. 1998;4(4):1055.
101. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. *Anticancer Res*. 2003;23(1A):363.
102. Ichiki K, Mitani N, Doki Y, Hara H, Misaki T, Saiki I. Regulation of activator protein-1 activity in the mediastinal lymph node metastasis of lung cancer. *Clin Exp Metastasis*. 2000;18(7):539.
103. Menon LG, Kuttan R, Kuttan G. Anti-metastatic activity of curcumin and catechin. *Cancer Lett*. 1999;141(1-2):159.
104. Lee A, Done ML. The use of nonpharmacologic techniques to prevent postoperative nausea and vomiting: a meta-analysis. *Anesth Analg*. 1999;88:1362.
105. Schlager A, Offer T, Baldissera I. Laser stimulation of acupuncture point P6 reduces postoperative vomiting in children undergoing strabismus surgery. *Brit J Anaesthesia*. 1998;81:529.
106. Al-Sadi M, Newman B, Julious SA. Acupuncture in the prevention of postoperative nausea and vomiting. *Anaesthesia*. 1997;52:658.
107. Dundee JW, Ghaly RG, Fitzpatrick KTJ, Abram WP, Lynch GA. Acupuncture prophylaxis of cancer chemotherapy-induced sickness. *J Royal Soc Med*. 1989;82:268.
108. Dundee JW, Chestnutt WN, Ghaly RG, Lynas AGA. Traditional Chinese acupuncture: a potentially useful antiemetic? *BMJ*. 1986;293:583.
109. NIH Consensus Conference. Acupuncture. *JAMA*. 1998;280(17):1518.
110. Petti F, Bangrazi A, Liguori A, Reale G, Ippoliti F. Effects of acupuncture on immune response related to opioid-like peptides. *J Tradit Chin Med*. 1998;18:55.
111. Wu B, Zhou RX, Zhou MS. [Effect of acupuncture on immunomodulation in patients with malignant tumors]. *Chung Kuo Chung His Chieh Ho Tsa Chih*. 1996;16:139.
112. Sato T, Yu Y, Guo SY, Kasahara T, Hisamitsu T. Acupuncture stimulation enhances splenic natural killer cell cytotoxicity in rats. *Jpn J Physiol*. 1996;46:131.
113. Wu B. [Effect of acupuncture on the regulation of cell-mediated immunity in patients with malignant tumours]. *Chen Tzu Yen Chiu*. 1995;20:67.
114. Liu CJ, Guo LJ, Jiao XM. [Effect of acupuncture on immunologic function and histopathology of transplanted mammary cancers in mice]. *Chung Kuo Chung His I Chieh Ho Tsa Chih*. 1995;15:615.
115. Wu B, Zhou RX, Zhou MS. [Effect of acupuncture on interleukin-2 level and NK cell immunoactivity of peripheral blood of malignant tumour patients]. *Chung Kuo Chung His Chieh Ho Tsa Chih*. 1994;14:537.
116. Yuan J, Zhou R. [Effect of acupuncture on T-lymphocyte and its subsets from the peripheral blood of patients with malignant neoplasm]. *Chen Tzu Yen Chiu*. 1993;18:174.

117. Bianchi M, Jotti E, Sacerdote P, Panerai AE. Traditional acupuncture increases the content of beta-endorphin in immune cells and influences mitogen induced proliferation. *Am J Chin Med.* 1991;19:101.
118. Filshie J, Redman D. Acupuncture and malignant pain problems. *Eur J Surg Oncol.* 1985;11:389.
119. Filshie J. Acupuncture for malignant pain. *Acupuncture in Medicine.* 1984;May:12.

Chapter 12: Nutrition and Lung Cancer

1. Lien HC, Sun WM, Chen YH, Kim H, Hasler W, Owyang C. Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circularvection. *Am J Physiol Gastrointest Liver Physiol.* 2003;284(3):G481.
2. Vutyavanich T, Kraissarin T, Ruangsri R. Ginger for nausea and vomiting in pregnancy: randomized, double-masked, placebo-controlled trial. *Obstet Gynecol.* 2001;97(4):577.
3. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. *Br J Anaesth.* 2000;84(3):367.
4. Sharma SS, Gupta YK. Reversal of cisplatin-induced delay in gastric emptying in rats by ginger (*Zingiber officinale*). *J Ethnopharmacol.* 1998;62(1):49.
5. White PF, Issioui T, Hu J, et al. Comparative efficacy of acustimulation (ReliefBand) versus ondansetron (Zofran) in combination with droperidol for preventing nausea and vomiting. *Anesthesiology.* 2002;97(5):1075.
6. Stern RM, Jokerst MD, Muth ER, Hollis C. Acupressure relieves the symptoms of motion sickness and reduces abnormal gastric activity. *Altern Ther Health Med.* 2001;7(4):91.
7. Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. *J Pain Symptom Manage.* 2000;20(5):374.
8. King CR. Nonpharmacologic management of chemotherapy-induced nausea and vomiting. *Oncol Nurs Forum.* 1997;24(7 Suppl):41.
9. Sakai F, Yoshida S, Endo S, Tomita H. Double-blind, placebo-controlled trial of zinc picolinate for taste disorders. *Acta Otolaryngol Suppl.* 2002;(546):129.
10. Voorrips LE, Goldbohm RA, Verhoeven DT, van Poppel GA, Sturmans F, Hermus RJ, van den Brandt PA. Vegetable and fruit consumption and lung cancer risk in the Netherlands Cohort Study on diet and cancer. *Cancer Causes Control.* 2000;11(2):101.
11. Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Clark LC, Marshall JR. Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial. *Cancer Epidemiol Biomarkers Prev.* 2002;11(11):1285.
12. Marchand JL, Luce D, Goldberg P, Bugel I, Salomon C, Goldberg M. Dietary factors and the risk of lung cancer in New Caledonia (South Pacific). *Nutr Cancer.* 2002;42(1):18.
13. Rachtan J. Dietary habits and lung cancer risk among Polish women. *Acta Oncol.* 2002;41(4):389.
14. Seow A, Poh WT, Teh M, et al. Diet, reproductive factors and lung cancer risk among Chinese women in Singapore: evidence for a protective effect of soy in nonsmokers. *Int J Cancer.* 2002;97(3):365.

15. Hirvonen T, Virtamo J, Korhonen P, Albanes D, Pietinen P. Flavonol and flavone intake and the risk of cancer in male smokers (Finland). *Cancer Causes Control*. 2001;12(9):789.
16. Voorrips LE, Goldbohm RA, Brants HA, van Poppel GA, Sturmans F, Hermus RJ, van den Brandt PA. A prospective cohort study on antioxidant and folate intake and male lung cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2000;9(4):357.
17. Le Marchand L, Murphy SP, Hankin JH, Wilkens LR, Kolonel LN. Intake of flavinoids and lung cancer. *J Natl Cancer Inst*. 2000;92(2):154.
18. Stefani ED, Boffetta P, Deneo-Pellegrini H, Mendilaharsu M, Carzoglio JC, Ronco A, Olivera L. Dietary antioxidants and lung cancer risk: a case-control study in Uruguay. *Nutr Cancer*. 1999;34(1):100.
19. Birkett NJ. Intake of fruits and vegetables in smokers. *Public Health Nutr*. 1999;2(2):217.
20. Cooper DA, Eldridge AL, Peters JC. Dietary carotenoids and lung cancer: a review of recent research. *Nutr Rev*. 1999;57(5 Pt 1):133.
21. Nyberg F, Agrenius V, Svartengren K, Svensson C, Pershagen G. Dietary factors and risk of lung cancer in never-smokers. *Int J Cancer*. 1998;78(4):430.
22. Mendilaharsu M, De Stefani E, Deneo-Pellegrini H, Carzoglio J, Ronco A. Phytosterols and risk of lung cancer: a case-control study in Uruguay. *Lung Cancer*. 1998;21(1):37.
23. Bandera EV, Freudenheim JL, Marshall JR, et al. Diet and alcohol consumption and lung cancer risk in the New York State Cohort (United States). *Cancer Causes Control*. 1997;8(6):828.

Chapter 13: Managing Your Health Care

1. Lee JS, Scott CB, Komaki R, Ettinger DS, Sause WT. Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2002;52(2):362.
2. Muers MF, Haward RA. Management of lung cancer. *Thorax*. 1996;51:557.
3. Rodriguez de Castro F, Diaz Lopez F, Serda GJ, Lopez AR, Gilart JF, Cabrera Navarro P. Relevance of training in transbronchial fine-needle aspiration technique. *Chest*. 1997;111(1):103.
4. Haponik EF, Cappellari JO, Chin R, Adair NE, Lykens M, Alford PT, Bowton DL. Education and experience improve transbronchial needle aspiration performance. *Am J Respir Crit Care Med*. 1995;151(6):1998.
5. Rayl JE, Pittman JM, Shuster JJ. Preclinical training in bronchoscopic diagnosis of cancer. *Chest*. 1988;93(4):824.